Status and phase
Conditions
Treatments
About
This Clinical Trial Aims to Evaluate the PK/PD Drug-Drug Interaction and Safety/Tolerability of Tegoprazan and Aspirin in Healthy Adult Male Volunteers.
Full description
Trial Objective
Primary Objective
Secondary Objective
Exploratory Objective
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Participants who have or have a history of clinically significant hepatobiliary diseases (e.g., severe hepatic impairment or viral hepatitis), renal diseases (e.g., severe renal impairment), neurological diseases, immune system disorders, respiratory diseases, gastrointestinal diseases, endocrine disorders, hematologic or neoplastic diseases, cardiovascular diseases (e.g., cardiac failure or Torsade de pointes), urinary system disorders, psychiatric disorders (e.g., mood disorder or obsessive-compulsive disorder), sexual dysfunction, or other relevant diseases
Participants who have a history of gastrointestinal diseases (e.g., Crohn's disease, ulcer, gastritis, gastric spasm, or gastroesophageal reflux disease) or gastrointestinal surgery (except for simple appendectomy or hernia surgery) that may affect the evaluations of the safety, pharmacokinetics, and pharmacodynamics of the investigational product
Participants who have hypersensitivity to P-CAB (Potassium-Competitive Acid Blocker), drugs of the same class, or any other drugs (e.g., Aspirin or other salicylates, antibiotics, or benzimidazole anthelmintics), or who have a history of clinically significant hypersensitivity
Participants with hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
Participants with positive serology results for hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or syphilis
Participants with a history of drug abuse or who test positive for drugs of abuse in a urine drug screening test
Participants with any of the following vital sign values measured in the sitting position after at least 3 minutes of rest at screening:
Participants with QTcB > 450 msec or clinically significant abnormal rhythm findings on 12-lead ECG at screening
Participants with one or more of the following results in clinical laboratory tests conducted during screening, including additional tests:
Participants who have taken any prescription drug or herbal medicine within 2 weeks prior to the scheduled date of the first administration of the investigational product, or any OTC drug, health functional food including liver function supplements, or vitamin preparation within 1 week prior to the scheduled date of the first administration of the investigational product (however, participants may be enrolled if other conditions are deemed reasonable by the investigator), or who are expected to take any such product
Participants who have taken drug-metabolizing enzyme-inducing drugs, such as barbiturates, or drug metabolism-inhibiting drugs, such as clarithromycin, within 1 month prior to the scheduled date of the first administration of the investigational product
Participants who have participated in another clinical trial (including a bioequivalence trial) and received an investigational product within 6 months prior to the scheduled date of the first administration of the investigational product
Participants who have donated whole blood within 2 months, or who have donated blood components or received a blood transfusion within 1 month prior to the scheduled date of the first administration of the investigational product.
Participants (however, participants who stopped smoking at least 3 months prior to the scheduled date of the first administration of the investigational product may be enrolled), or heavy smokers (10 cigarettes/day), or participants who are unable to abstain from smoking until the end of the clinical trial
Participants who regularly consume alcohol (>21 units/week; 1 unit = 10 g of pure alcohol) or are unable to abstain from alcohol from 3 days prior to the scheduled date of the first administration of the investigational product until the end of the clinical trial
Participants who have regularly consumed excessive caffeine (>5 units/day; 1 unit = 80 mg of caffeine) or are unable to refrain from consuming caffeine-containing foods or beverages (e.g., coffee, tea (including black tea and green tea), carbonated beverages, coffee beverages, coffee milk, tonic drinks, and energy drinks) from 3 days prior to the scheduled date of the first administration of the investigational product until the end of the clinical trial
Participants who have consumed or are unable to refrain from consuming grapefruit, grapefruit juice, or grapefruit-containing foods from 3 days prior to the scheduled date of the first administration of the investigational product until the end of the clinical trial
Participants who have unusual dietary habits (e.g., consumption of ≥1 L of grapefruit juice per day) or are unable to consume the standardized diet provided by the Clinical Trials Center during the inpatient period
Participants who, or whose spouse or partner, are unable to use a contraceptive method considered highly effective throughout the entire clinical trial and for at least 4 weeks after the last administration of the investigational product, and participants who do not agree not to donate sperm during that period
[Contraceptive Methods Considered Highly Effective]
Participants determined by the investigator to be unsuitable for participation in this clinical trial for reasons other than those listed above.
Primary purpose
Allocation
Interventional model
Masking
34 participants in 1 patient group
Loading...
Central trial contact
Yugyeong Park; Heeju Ahn
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal